Stryker (SYK) stock
Health Care · Health Care Equipment
Stryker (SYK) is a Health Care Equipment company in the Health Care sector, headquartered in Kalamazoo, Michigan. As of October 23, 2026, SYK closed at $307.15, a market capitalization of $117.81 billion, the 105th largest company in the S&P 500. Over the last twelve months it generated $25.84 billion in revenue (+9% year over year) and $4.70 billion in free cash flow. The stock trades at 31.8x trailing earnings and 18.4x forward earnings.
- 1-year total return: -18.9% (dividends reinvested)
- 5-year return: +3.3% a year
- 52-week range: $267.00 – $389.33
- Gross margin 65.6%, operating margin 27.0%
- Dividend yield: 1.15%, 16 straight years of increases
- FI Handbook report card: B- across 10 metrics
- 17th largest of 60 Health Care stocks in the S&P 500
SYK price chart
1Y price change: -19.8% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| SYK | +12.7% | -11.9% | -18.9% | +6.3% | +3.3% | +11.7% | +19.5% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1980.
SYK key statistics
- Market cap
- $117.8B
- #105 in S&P 500
- P/E (TTM)
- 31.8x
- Forward P/E
- 18.4x
- EPS (TTM)
- $9.65
- Revenue (TTM)
- $25.8B
- +9%
- Free cash flow
- $4.7B
- Gross margin
- 65.6%
- Operating margin
- 27.0%
- Return on equity
- 16.5%
- Dividend yield
- 1.15%
- 52-week range
- $267.00 – $389.33
- Beta
- 0.78
- Price / sales
- 4.6x
- EV / EBITDA
- 17.6x
- Debt / equity
- 0.64x
- Employees
- 56,000
SYK report card
B-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth9.4%C
- Gross margin65.6%A
- Operating margin27.0%B
- FCF margin18.2%B
- Return on equity16.5%B
- Net debt / EBITDA1.6xC
- Forward P/E18.4xB
- PEG ratio1.3xB
- Shareholder yield1.1%D
- Share count change / yr0.3%C
Stryker financials
Revenue went from $11.3B in fiscal 2016 to $25.1B in fiscal 2025, growing 9.3% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.3B | $12.4B | $13.6B | $14.9B | $14.4B | $17.1B | $18.4B | $20.5B | $22.6B | $25.1B |
| Gross profit | $7.5B | $8.2B | $8.9B | $9.7B | $9.1B | $11.0B | $11.6B | $13.1B | $14.4B | $16.1B |
| Operating income | $2.2B | $2.3B | $2.5B | $2.7B | $2.2B | $2.6B | $2.8B | $3.9B | $3.7B | $4.9B |
| Net income | $1.6B | $1.0B | $3.6B | $2.1B | $1.6B | $2.0B | $2.4B | $3.2B | $3.0B | $3.2B |
| EPS (diluted) | $4.35 | $2.68 | $9.34 | $5.48 | $4.20 | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 |
| Free cash flow | $1.4B | $961.0M | $2.0B | $1.5B | $2.8B | $2.7B | $2.0B | $3.1B | $3.5B | $4.3B |
| Buybacks | $13.0M | $230.0M | $300.0M | $307.0M | $0 | $0 | — | — | — | — |
| Dividends paid | $568.0M | $636.0M | $703.0M | $778.0M | $863.0M | $950.0M | $1.1B | $1.1B | $1.2B | $1.3B |
| Diluted shares | 378.5M | 380.1M | 380.3M | 379.9M | 380.3M | 382.3M | 382.2M | 383.7M | 385.6M | 386.5M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into SYK?
A reverse DCF asks what growth the current price requires. With an enterprise value of $129.8B and $4.7B of trailing free cash flow, Stryker needs to grow free cash flow about 18.7% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 9.0% a year over the last five years.
P/E ratio history
Current 36.6x vs. median 32.9x (10th–90th percentile 16.0x–62.9x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
SYK dividend
- Dividend yield
- 1.15%
- Annual dividend
- $3.52
- Years of increases
- 16
- 5-yr dividend growth
- 7.6%
- per year
- Payout ratio
- 36%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
SYK earnings
Next report: October 29, 2026. Stryker has beaten EPS estimates 1 quarters in a row. Last quarter's revenue was $6.6B (+9% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 30, 2026 | $3.49 | $3.69 | +5.8% |
| Apr 30, 2026 | $2.98 | $2.60 | -12.9% |
| Jan 29, 2026 | $4.40 | $4.47 | +1.7% |
| Oct 30, 2025 | $3.13 | $3.19 | +1.9% |
| Jul 31, 2025 | $3.07 | $3.13 | +1.9% |
| May 1, 2025 | $2.73 | $2.84 | +4.0% |
| Jan 28, 2025 | $3.87 | $4.01 | +3.5% |
| Oct 29, 2024 | $2.77 | $2.87 | +3.5% |
Stocks like SYK
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABT Abbott Laboratories | +1.16% | -16% | $179.4B | 38.6x | Compare |
 ISRG Intuitive Surgical | +1.90% | -18% | $159.8B | 54.7x | Compare |
 MDT Medtronic plc. | -1.22% | +5% | $122.0B | 23.4x | Compare |
 BSX Boston Scientific | -0.70% | -55% | $66.2B | 18.5x | Compare |
 BDX Becton, Dickinson and | -0.75% | +39% | $54.2B | 46.3x | Compare |
 EW Edwards Lifesciences Corporatio | -1.13% | +16% | $51.3B | 53.0x | Compare |
 IDXX IDEXX Laboratories | -1.13% | -12% | $44.1B | 39.4x | Compare |
 RMD ResMed | -0.08% | -4% | $35.6B | 24.2x | Compare |
SYK news
- Stryker (SYK) Tests Its Valuation After Sonopet 3 Clearance · Oct 23, 2026
- Stryker (SYK) Stock May Trade At A Discount Despite FDA Clearance · Oct 23, 2026
- Global Laparoscope Market Size, Share, Trends, and Forecast for Rigid and Flexible Scopes, 2026-2032 | 4K, 3D, and Integrated Systems Fuel 6.3% CAGR to $1.3 Billion · Oct 22, 2026
- Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release · Oct 22, 2026
- PAHC or SYK: Which Is the Better Value Stock Right Now? · Oct 21, 2026
SYK stock FAQ
What is SYK's market cap?
Stryker's market capitalization is $117.81 billion as of October 23, 2026, ranking 105th in the S&P 500.
What is SYK's P/E ratio?
SYK trades at a trailing price-to-earnings ratio of 31.8x and a forward P/E of 18.4x. Its median P/E over the period we track is 32.9x.
Does SYK pay a dividend?
Yes. Stryker pays $3.52 per share a year, a 1.15% yield. It has raised its dividend 16 years in a row. Dividends grew 7.6% a year over the last five years.
How much has SYK stock returned?
Including reinvested dividends, SYK returned -18.9% over one year, +3.3% a year over five years, +11.7% a year over ten years through October 23, 2026.
Is SYK stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Stryker must grow free cash flow about 19% a year for the next decade. Its free cash flow grew 9% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
When does SYK report earnings?
Stryker is expected to report earnings on October 29, 2026. It has beaten EPS estimates 1 quarters in a row.
How many employees does Stryker have?
Stryker has about 56,000 full-time employees, or $461,375 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology